论文部分内容阅读
目的探讨门冬氨酸钾镁和腺苷蛋氨酸在胆汁淤积性病毒性肝炎患者中的临床疗效。方法 80例胆汁淤积性病毒性肝炎患者分为对照组和试验组,各40例。试验组静脉滴注门冬氨酸钾镁30 m L,对照组静脉滴注腺苷蛋氨酸1000mg,连续治疗4周,比较2组的临床疗效,观察2组患者治疗前后的临床症状和肝功能指标改善情况。结果试验组有效率为95.0%,显著高于对照组的85.0%(P<0.05)。治疗后,2组谷丙转氨酶、谷草转氨酶、总胆红素、直接胆红素、碱性磷酸酶和γ-谷氨酰转肽酶显著低于治疗前,且试验组显著低于对照组(P<0.05)。试验组临床症状改善率为85.0%,显著高于对照组的57.5%(P<0.05)。试验组不良反应发生率为7.5%,显著低于对照组的17.5%(P<0.05)。结论门冬氨酸钾镁对胆汁淤积性病毒性肝炎的临床疗效显著,且不良反应发生率低。
Objective To investigate the clinical efficacy of potassium magnesium aspartate and adenosylmethionine in patients with cholestatic viral hepatitis. Methods Eighty patients with cholestatic viral hepatitis were divided into control group and trial group, 40 cases each. The experimental group intravenous injection of potassium magnesium aspartate 30 m L, the control group intravenous infusion of adenosine methionine 1000mg, continuous treatment for 4 weeks, the clinical efficacy of two groups were compared to observe the clinical symptoms and liver function parameters of two groups before and after treatment Improve the situation. Results The effective rate of the experimental group was 95.0%, which was significantly higher than that of the control group (85.0%, P <0.05). After treatment, the two groups of alanine aminotransferase, aspartate aminotransferase, total bilirubin, direct bilirubin, alkaline phosphatase and γ-glutamyl transpeptidase were significantly lower than before treatment, and the experimental group was significantly lower than the control group P <0.05). The clinical symptom improvement rate was 85.0% in the experimental group, which was significantly higher than 57.5% in the control group (P <0.05). The incidence of adverse reactions in the experimental group was 7.5%, which was significantly lower than that in the control group (17.5%, P <0.05). Conclusion The clinical efficacy of potassium-magnesium aspartate on cholestatic viral hepatitis is significant and the incidence of adverse reactions is low.